Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Tango Therapeutics, Inc. | Director | Common Stock | 31.3K | $118K | $3.78 | Nov 18, 2024 | Direct |
Tango Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 37.5K | Jun 5, 2024 | Direct | ||
Surrozen, Inc./DE | Director | Option (right to buy) | 1.33K | Jun 5, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
TNGX | Tango Therapeutics, Inc. | Nov 14, 2024 | 2 | $74K | 4 | Nov 18, 2024 | Director |
TNGX | Tango Therapeutics, Inc. | Jun 5, 2024 | 2 | $0 | 4 | Jun 7, 2024 | Director |
SRZN | Surrozen, Inc./DE | Jun 5, 2024 | 1 | $0 | 4 | Jun 6, 2024 | Director |
TNGX | Tango Therapeutics, Inc. | Jun 6, 2023 | 2 | $0 | 4 | Jun 8, 2023 | Director |
SRZN | Surrozen, Inc./DE | May 18, 2023 | 1 | $0 | 4 | May 19, 2023 | Director |
TNGX | Tango Therapeutics, Inc. | Jun 8, 2022 | 1 | $0 | 4 | Jun 28, 2022 | Director |
SRZN | Surrozen, Inc./DE | Jun 7, 2022 | 1 | $0 | 4 | Jun 9, 2022 | Director |
SRZN | Surrozen, Inc./DE | Aug 11, 2021 | 0 | $0 | 3 | Aug 16, 2021 | Director |
TNGX | Tango Therapeutics, Inc. | Aug 10, 2021 | 0 | $0 | 3 | Aug 12, 2021 | Director |